Sanofi Pasteur has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its Prophylactic vaccine against staphylococcus, including methicillin-resistant staphylococcus aureus or MRSA.
Under the terms of the agreement, Sanofi Pasteur will support the joint, pre-clinical development of the product, working co-operatively with Syntiron, and be responsible for all future developments, regulatory approval, and commercialization of the vaccine. The agreement includes an undisclosed initial licensing fee, milestone payments, and royalty payments on future sales of the product.
Wayne Pisano, president and chief executive officer of Sanofi Pasteur, said: “This agreement with Syntiron is just another example of Sanofi Pasteur’s interest in partnering with biotechs to produce innovative vaccines to address public health needs. Along with our development of a vaccine to prevent
Clostridium difficile infection, the successful development of a vaccine to prevent MRSA would be a major achievement in combating hospital-associated infections.”